



ASPH/O

American Society of Pediatric Hematology/Oncology Sixteenth Annual Meeting ~ May 1-4, 2003 Sheraton Seattle & Washington State Convention and Trade Center

Thursday, May 1	Friday, May 2	Saturday, May 3	Sunday, May 4
<p>7:30am – 8:30am ASPHO Workshops ~ Hemoglobinopathy ~ Bone Marrow Failure</p> <p>8:45am – 9:00am ASPHO President's Welcome</p> <p>9:00am – 11:30am ASPHO Symposium I ~ Thalassemia Intermedia</p> <p>11:30am – 12:30pm 2nd Annual Frank A. Oski Memorial Lecture ~ Journey from Thalassemia to Stem Cells</p> <p>12:30pm – 2:30pm ASPHO Corporate Forum Luncheons</p> <p>2:30pm – 3:00pm Dessert Break with Exhibits</p> <p>3:00pm – 5:00pm ASPHO Presidential Symposium ~ Medicine for the Individual in the 21st Century</p> <p>5:00pm – 6:30pm ASPHO Opening Reception with Exhibits</p>	<p>7:15am – 8:15am ASPHO Workshops ~ Immune Thrombocytopenia ~ Pediatric Cancer: Hematologic Support During Cancer Therapy</p> <p>8:30am – 10:30am ASPHO Symposium II ~ Immunology and Immunotherapy of Pediatric Malignancies</p> <p>10:30am – 11:00am Break with Exhibits</p> <p>11:00am – 12:00 noon ASPHO Workshops ~ Young Investigators ~ Practice Management ~ Hereditary Bleeding Disorders</p> <p>12:00 noon – 2:00pm ASPHO Corporate Forum Luncheons</p> <p>2:00pm – 4:30pm ASPHO Symposium III ~ Regulation of Hematopoiesis</p> <p>4:30pm – 5:00pm ASPHO Distinguished Career Award Presentation</p> <p>5:00pm – 5:30pm ASPHO Business Meeting</p> <p>5:30pm – 6:00pm ASPHO Distinguished Career Award Reception</p> <p>6:15pm – 7:45pm Battle of the ASPHO Superstars</p>	<p>7:30am – 8:30am ASPHO Workshops ~ Histiocyte ~ Thrombotic Disorders</p> <p>7:30am – 8:30am Meet the Experts Sessions TICKETED EVENT ~ Approaches to Management of Autoimmune Cytopenias ~ Approaches to the Child with Hemolytic Anemia</p> <div style="border: 1px solid purple; border-radius: 50%; padding: 10px; text-align: center; margin: 10px auto; width: fit-content;"> <p>PAS/ASPHO Joint Programming Begins Washington State Convention and Trade Center</p> </div> <p>9:15am – 12:15pm PAS/ASPHO Mini Courses ~ Cancer in Adolescents and Young Adults: Ultimate Paradigm of Adolescent Medicine? ~ Pediatric Rare Tumors</p> <p>12:00pm – 3:00pm PAS Educational Workshops</p> <p>1:00pm – 3:00pm PAS/ASPHO Original Science Abstracts ~ Hematology/Oncology Platform I</p> <p>3:15pm – 5:15pm PAS/ASPHO Topic Symposium ~ New Genetics of Childhood Acute Leukemia</p> <p>5:15pm – 7:15pm PAS/ASPHO Posters I, Exhibits & PAS Opening Reception ~ Hematology/Oncology Posters I</p>	<p>7:00am – 8:00am PAS Meet the Professor Breakfast TICKETED EVENT ~ Hematology/Oncology</p> <p>8:00am – 10:00am PAS/ASPHO Original Science Abstracts ~ Hematology/Oncology Platform II</p> <p>8:00am – 10:00am PAS Educational Workshops</p> <p>11:45am – 1:45pm PAS/ASPHO Posters & Exhibits ~ Hematology/Oncology Posters II</p> <p>2:00pm – 4:00pm PAS Educational Workshops</p> <p>2:30pm – 4:00pm PAS/ASPHO State of the Art Plenary ~ Primary Immunodeficiency Diseases, A Hematologic and Molecular Approach</p> <p>4:15pm – 6:15pm PAS/ASPHO Topic Symposium ~ "Home from War" – Follow Up Post Hematopoietic Stem Cell Transplant</p>

ASPH/O

The American Society of
Pediatric Hematology/Oncology

Join us in Seattle, where ASPHO and PAS will host aligned annual meetings. Joint symposia and original science abstracts will all be held at the Washington State Convention and Trade Center. We look forward to the synergy created by this alliance. The ASPHO Annual Meeting will be hosted at the Sheraton Seattle just prior to the PAS.

Registration Information

Please read the registration instructions carefully

If you are a **member of APS, SPR or APA**, please **register for the PAS meeting**. The PAS registration form includes an option to indicate that you will attend the ASPHO program. You will be allowed access to the programming at the ASPHO meeting at no additional registration fee with your PAS badge. Contact PAS for further details at info@pas-meeting.org, register on-line at www.pas-meeting.org or call 281-419-0052.

If you are a **member of ASPHO or none of the above and/or a pediatric hematologist/oncologist** and wish to attend the ASPHO meeting, please **register directly with ASPHO**. The ASPHO registration forms include an option to indicate that you will attend the PAS programming. Your registration will be forwarded to PAS, and you will be entitled to attend the ASPHO program, the joint programming and the PAS program offerings with your ASPHO badge at no additional registration fee or process. Contact ASPHO to register or to request program materials (847-375-4716; info@aspho.org; www.aspho.org).

Confirmation

You will receive separate confirmations for each meeting. If you register for ASPHO and indicate your attendance at the PAS meeting, you will receive confirmation from both organizations.

Contact ASPHO for further details on the ASPHO Annual Meeting.

American Society of Pediatric
Hematology/Oncology
4700 W. Lake, Glenview, IL 60025-1485
Phone: 847-375-4716 Fax: 877-734-9557
Email: info@aspho.org
URL: www.aspho.org

Housing Information

The Sheraton is the headquarter hotel for ASPHO. Call the ASPHO housing bureau at (888) 877-0255 or for international callers (206) 461-5881 by April 1st to secure lodging.

Program Purpose

The 15th Annual Meeting of The American Society of Pediatric Hematology/Oncology will present current data from research concerning causes, diagnosis and management of hematology/oncology problems in children and will apply it to clinical practice.

Conference Objectives

- Describe the natural history of thalassemia intermedia and identify new molecular tools for diagnosis and new chemotherapy approaches for treatment.
- Identify key clinical situations where individual genetic polymorphisms predict risk, affect management and determine outcome in childhood cancer.
- Discuss mechanisms for manipulation of the cellular immune system as a novel strategy for treatment of pediatric malignancies.
- Discuss recent advances in the regulation of hematopoiesis, including potential mechanisms for manipulating the evolution of primitive stem cells.
- Assemble a network of professional colleagues with common interests to solve problems, share experiences in the setting of interactive workshops and provide mutual professional support.

Continuing Education Credit

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the University of Cincinnati College of Medicine and ASPHO. The University of Cincinnati College of Medicine is accredited by ACCME to provide continuing medical education (CME) for physicians.

The University of Cincinnati College of Medicine designates this CME activity for a maximum of 13 hours in Category 1 credit toward the American Medical Association Physician's Recognition Award. Each physician should claim only those hours of credit he or she actually spent in the educational activity.

All faculty are required to disclose to program participants any relationship, including financial interest or affiliation(s) with a commercial company, as well as discussion of unlabeled uses. Full disclosure of faculty relationships will be made available to program participants by verbal and/or written statements prior to the activity.

The material presented at this meeting represents the opinion of the speakers and not necessarily the views of the University of Cincinnati College of Medicine or ASPHO.

If registered through ASPHO, CME credit for the ASPHO program is included in your registration fees. However, if CME credit hours are desired for any and all programming hosted at the Washington State Convention and Trade Center, a PAS-assessed CME processing fee is required. Refer to the procedures on page 4 or see the PAS CME Desk on-site at the Washington State Convention and Trade Center for more details **BEFORE** you attend PAS/ASPHO joint programming.

ASPHO Programming on
Thursday and Friday is at the
Sheraton Seattle Hotel.

Thursday, May 1, 2003

7:30am – 8:30am

Hemoglobinopathy Workshop (301)

*Peter A. Lane, Jr., University of Colorado,
Denver, CO and Russell E. Ware, Duke
University Medical Center, Durham, NC*

Synopsis not available.

Bone Marrow Failure Workshop (302)

*Jeffrey Hord, Children's Hospital Medical
Center, Akron, OH and Adriana Vlachos,
Schneider Children's Hospital, New Hyde Park,
NY*

The workshop will present an update on the diagnosis and management of acquired severe aplastic anemia in childhood covering both marrow transplantation and immunosuppression. A review of the findings from the Diamond-Blackfan Anemia Registry will also be presented. Current clinical trials in the area of marrow failure disorders will be reviewed. Participants are encouraged to submit interesting cases or study proposals in advance of the conference to be considered for discussion during the workshop. Send proposals to: jhord@chmca.org.

8:45am – 9:00am

President's Welcome

*Beverly Lange, Children's Hospital of Philadelphia,
Philadelphia, PA*

9:00am – 11:30am

Symposium on Thalassemia Intermedia

*Moderator: Elliot P. Vichinsky, Children's
Hospital at Oakland, Oakland, CA*

Thalassemia intermedia is a complex clinical syndrome with marked clinical variability. Its prevalence in North America is rapidly increasing



due to immigration patterns and changing demographics. Pilot data suggests experimental therapy may replace the need for transfusions in this disorder. However, understanding the natural history and the genetic modifiers affecting clinical expression are essential before such therapy can be offered.

Genetic Modifiers of Thalassemia Intermedia
Sir David Weatherall, Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, United Kingdom

Natural History of Thalassemia Intermedia
Nancy F. Olivieri, Hospital for Sick Children, Toronto, ON, Canada

Chemotherapy for Thalassemia
Elliot P. Vichinsky, Children's Hospital at Oakland, Oakland, CA

11:30am – 12:30pm
Journey from Thalassemia to Stem Cells

2nd Annual Frank A. Oski Memorial Lecture

Stuart H. Orkin, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

The blood (or hematopoietic) system is a paradigm for mammalian development in which stem cells ultimately give rise to diverse specialized cells. This presentation will review the genetic control of blood cell development. Emphasis will be given to how transcription factors program specific lineages by both positive and antagonistic mechanisms. The relevance of understanding normal blood cell development to leukemia pathogenesis will be highlighted through the discussion of the role of leukemia-associated genes in blood stem cells.

12:30pm – 2:30pm
Corporate Forum Luncheons

These sessions are commercially supported events. Pre-registration is required by responding to the invitation sent to all ASPHO members by the supporting company.

Challenges in Haemostasis and Thrombosis: The Inhibitor Patient (201)

Speakers to be determined.

With the introduction of factor concentrates and new therapies, the treatment of coagulation disorders has advanced significantly. Some of these patients develop inhibitors to concentrates and present a whole set of different problems. These are the most challenging to treat in terms of therapeutic options and costs. This symposium will review current treatment options and introduce the latest trends and data to assist the clinician in these challenges. Participants in the session will be able

to discuss inhibitor laboratory measurement, classification and diagnosis, as well as current therapy options and potential outcomes.

Supported by an unrestricted educational grant from Aventis Behring.

Pediatric Trials—Design, Development and Demand (202)

Synopsis and Speakers to be determined.

Supported by an unrestricted educational grant from ILEX/Bioenvision.

2:30pm – 3:00pm
Dessert Break with Exhibits

3:00pm – 5:00pm
Medicine for the Individual in the 21st Century

Presidential Symposium

Moderator: Beverly Lange, Children's Hospital of Philadelphia, Philadelphia, PA

This year's Presidential Symposium follows up on Dr. Dover's inaugural Oski Memorial Lecture concerning the paradigm shift from "Treatment of the Disease" in the 20th century to "Treatment of the Individual" in the 21st. Each speaker will address a clinically important situation where individual genetic polymorphisms predict risk, affect management, and determine outcome.

Cardiac Ion Channel Mutations in Drug-Induced Sudden Childhood Death
Stephen A.N. Goldstein, Yale University School of Medicine, New Haven, CT

Genetic Modulations of Host Defense in Children with Cancer
Stephen J. Chanock, National Cancer Institute, Bethesda, MD

Pharmacogenetic Strategies to Individualize Therapy for ALL
Howard McLeod, Washington University School of Medicine, St. Louis, MO

5:00pm – 6:30pm
Opening Reception with Exhibits

Friday, May 2, 2003

7:15am – 8:15am
Immune Thrombocytopenia Workshop (303)

Co-Chairs: Victor S. Blanchette, The Hospital for Sick Children, Toronto, ON, Canada and Thomas Kuehne, University Children's Hospital, Basel, Switzerland

This ITP update will focus on complex secondary ITP in children—in particular, refractory, primary

chronic ITP and the complex combined cytopenias in childhood including Evan's syndrome and autoimmune lymphoproliferative syndrome (ALPS). The potential role of newer therapies such as anti-CD20 (Rituximab) will be discussed.

7:15am – 8:15am
Pediatric Cancer Workshop: Hematologic Support During Cancer Therapy (304)

Co-Chairs: Jeffrey A. Moscow, University of Kentucky Medical Center, Lexington, KY and Peter C. Adamson, Children's Hospital of Philadelphia, Philadelphia, PA

This workshop will focus on two topics: (1) thresholds for prophylactic transfusions in pediatric cancer patients and (2) the use of novel long-acting cytokines during chemotherapy.

8:30am – 10:30am
Symposium on Immunology and Immunotherapy of Pediatric Malignancies

Moderator: Paul Sondel, University of Wisconsin, Madison, WI

This session will address the influence of cancer and conventional cancer therapy on the immune system. Therapeutic approaches using vaccines, gene transfer technology and adoptive immunotherapy to provide T cell reactivity against childhood cancers will be summarized using data from preclinical models and clinical trials. Antibody directed cancer cell cytotoxicity approaches in murine models and clinical settings will be described along with pathways by which tumors escape from immunotherapy.

Endogenous Immunity to Tumors: Does it Exist?
Crystal L. Mackall, National Cancer Institute, Bethesda, MD

Adoptive Cellular Immunotherapy of Pediatric Tumors
Malcolm K. Brenner, Baylor College of Medicine, Houston, TX

Antibody Directed Cellular Cytotoxicity of Childhood Cancer: Efficacy and Escape
Paul Sondel, University of Wisconsin, Madison, WI

10:30am – 11:00am
Break with Exhibits

11:00am – 12:00 noon
Young Investigators Workshop (305)
Patricia Massicotte, Hospital for Sick Children, Toronto, ON, Canada and John M. Maris, Children's Hospital of Philadelphia, Philadelphia, PA

This informal panel discussion session will offer hem/onc fellows and junior faculty several perspectives on developing an academic career, as well as insights on balancing the development of clinical and/or bench research programs with other patient care, teaching, and family responsibilities. Information concerning the COG Young Investigator Initiative as well as other young investigator funding and training opportunities will be presented. Participants will be encouraged to discuss issues of interest or concern with several current and recent young investigators to learn effective career management. Participants will also have the opportunity to network with each other.

Practice Management Workshop (306)

John J. Hutter, University of Arizona, Tucson, AZ

The 2003 Practice Management Workshop will discuss strategies for contracting for pediatric hematology/oncology services. The session will also focus on conversion factors modeled for hematology/oncology. The workshop will encourage audience participation and discussion.

11:00 am–12:00 noon

Hereditary Bleeding Disorders Workshop (307)

Pedro A. de Alarcon, University of Virginia, Charlottesville, VA and Marilyn Manco-Johnson, Mountain States Regional Hemophilia Center, Aurora, CO

The workshop will focus on developing consensus guidelines for bleeding disorders. A report on the management consensus developed at last year's workshop will be presented. Various clinical scenarios and therapeutic options will also be presented for discussion.

12:00pm – 2:00pm

Corporate Forum Luncheons

These sessions are commercially supported events. Pre-registration is required by responding to the invitation sent to all ASPH/O members by the supporting company.

Attaining Hemostasis in the Pediatric Cancer Patient: Updates and Innovations (203)

Harold Roberts, Marc Carr, Don Gabriel and Stephanie Seremetis

Excessive bleeding can cause life-threatening complications in pediatric hematology/oncology patients. A thorough knowledge of hemostasis management techniques, established and new, is imperative for the pediatric hematologist/oncologist. This session will cover bleeding diatheses in pediatric patients, along with newly

conceived perspectives pertaining to the coagulation cascade, monitoring of hemostatic agents, and an update on the use of recombinant FVIIa. Participants in the course will be able to discuss new theories of the coagulation cascade and the importance of monitoring the efficacy of hemostatic agents, explain the safety and efficacy of treatments used in bone marrow transplant related hemorrhage, and the hematologic indicators monitored in this condition. Participants will also be able to compare the advantages and disadvantages of hemorrhage treatments used in pediatric hematology/oncology patients, and assess the most recent data available on the rFVIIa hemophilia clinical trials.

Supported by an unrestricted educational grant from Novo-Nordisk Pharmaceuticals, Inc.

Enhancing Adherence to Challenging Treatment Regimens in Children and Adolescents (204)

Ralph A. Grupp, Children's Hospital, Cincinnati, OH, Leonard A. Valentino, Rush Medical School, Chicago, IL and Prasad Mathew, University of New Mexico, Albuquerque, NM

A number of factors have been shown to be associated with successful treatment adherence among families with children who have chronic diseases. This symposium will explore current research on adherence in children and adolescents with chronic diseases, and is designed to help practitioners develop successful management strategies for children with conditions that require constant care. Participants in this session will be able to identify factors associated with adherence to challenging treatment regimens, describe what interventions can enhance adherence, educate caregivers on the management of central venous access devices, and encourage the transition of care from parents to adolescents.

Supported by an unrestricted educational grant from Wyeth Pharmaceuticals

2:00pm – 4:30pm

Symposium on Regulation of Hematopoiesis

Moderator: Peter E. Newburger, University of Massachusetts, Worcester, MA

This symposium will examine the rapidly advancing fields of stem cell plasticity, the mechanisms of lineage commitment and development in hematopoietic stem cells, and the role of cytokines in the direction of stem cell differentiation.

Hematopoietic Development and Stem Cells: Formation and Function

Stuart H. Orkin, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

Manipulation of Hematopoietic Stem Cell Outcomes

Connie Eaves, University of British Columbia, Vancouver, BC, Canada

Regulation of Hematopoiesis by G-CSF

Daniel C. Link, Washington University School of Medicine, St. Louis, MO

4:30pm – 5:00pm

Distinguished Career Award Presentation

5:00pm – 5:30pm

ASPHO Annual Business Meeting

5:30pm – 6:00pm

Distinguished Career Award Reception

6:15pm – 7:45pm

Battle of the ASPHO Superstars

Moderators: Holcombe Grier, Dana Farber Cancer Institute, Boston, MA and Cliff Takemoto, Johns Hopkins University School of Medicine, Baltimore, MD

Saturday, May 3, 2003

7:30am – 8:30am

Histiocyte Workshop (308)

Kenneth McClain, Texas Children's Hospital, Houston, TX and Jan-Inge Henter, British Columbia Children's Hospital, Vancouver, BC, Canada

This session will update participants on the latest scientific discoveries in the histiocytic diseases, including the findings presented at the Histiocyte Society meeting in Portugal. The workshop will discuss LCH-III protocol, registration and updates and present updated results of HLH-94 protocol and new HLH-2003 protocol.

Thrombotic Disorders Workshop (309)

Patricia Massicotte, Hospital for Sick Children, Toronto, ON, Canada and Lori Luchtman-Jones, Washington University School of Medicine, St. Louis, MO

Randomized, controlled trials for pediatric patients with thrombotic disorders are needed. Recommendations for the treatment and evaluation of thrombotic disorders in children are not well validated and are generally derived from studies and consensus statements for adult patients and from case series in children. The developing consortium of pediatric subspecialists who treat thrombotic disorders is identifying priorities for clinical studies and recruiting participating centers. Until results from pediatric studies are available,



clinicians must continue to develop practice strategies. In this workshop, two cases illustrative of common thrombotic problems in pediatric patients will be discussed. Current publications and a panel of experts will be available to help the audience develop a rational approach to patient management.

Participants will work in groups to develop a diagnostic and therapeutic strategy for one of two clinical cases: (1) new-onset transient ischemic attack with patent foramen ovale; (2) deep venous thrombosis. At the conclusion of the session, recommendations will be presented to the entire group.

7:30am – 8:30am

Meet the Expert Sessions

TICKETED SESSIONS

- Advance registration required.
- Attendance is limited to 20 participants in order to maintain an interactive format.
- To register, use the registration form provided in the ASPHO brochure.

Approaches to Management of Autoimmune Cytopenias (401)

George R. Buchanan, University of Texas Southwestern Medical Center, Dallas, TX


The following topics will be the focus of discussion in this interactive session: initial management of the child with ITP; Optimal treatment of the child with severe chronic refractory ITP (as well as the definition of such patients); diagnosis and management of chronic benign (autoimmune) neutropenia; autoimmune hemolytic anemia during infancy and childhood: what is the prognosis and what are the treatment options?

Approaches to the Child with Hemolytic Anemia (402)

Bertil E. Glader, Stanford University School of Medicine, Stanford, CA

Participants will have the opportunity to present ideas, interesting or challenging cases, and gain new perspectives on the treatment of hemolytic anemia in children through a facilitated, informal discussion.

Topics for discussion will include initial assessment and management of the child with hemolytic anemia, and enzymatic and membrane disorders that may cause hemolytic anemia.



9:15am – 12:15pm

3300 Cancer in Adolescents and Young Adults: Ultimate Paradigm of Adolescent Medicine?

PAS/ASPHO Mini Course

Chair: Archie Bleyer, University of Texas M. D. Anderson Cancer Center, Houston, TX

The primary objective of this Mini Course is to convey the array of issues intrinsic to caring for older adolescents and young adults with chronic, life threatening disease. For several reasons, cancer provides an ideal paradigm for this adolescent/young adult challenge.

1. The spectrum of disease is broader for cancer at many levels of biological organization than it is for any other disease. Virtually all organ systems and organs may be diseased in patients with cancer, whether due to the disease or its treatment. The affected organs include CNS, hematopoietic, cardiovascular, hepatic, renal, endocrine, musculoskeletal, immune, pulmonary, gastrointestinal, cutaneous, ocular, otic and oral tissues.
2. The affected levels of biological organization include molecular, cellular, tissue, organ, organ system, connective, and psychological. The latter is particularly challenging among adolescents with cancer.
3. The clinical and translational research programs in oncology are among the most organized medical enterprises at the national and tertiary center level in all of medicine, with the cooperative infrastructure that has supported this success among the most successful in the history of science. The advances among children with cancer have been among the most dramatic in the history of medicine.
4. Despite the organizational achievements, there is emerging evidence that patients with cancer in this age group have been ignored relative to the scientific and clinical focus that has been successfully applied to younger and older patients with malignant disease.

Overview

Archie Bleyer, University of Texas M. D. Anderson Cancer Center, Houston, TX

The Adolescent and Young Adult Gap in Cancer Care and Outcome

Jeffrey Carlton Murray, Cook Children's Medical Center, Fort Worth, TX

Sarcomas in Young Adults: Strategies for Enhanced Accrual to Clinical Trials

Karen Albritton, Primary Children's Medical Center, Huntsman Cancer Center, Salt Lake City, UT

Adolescent and Young Adults with Malignant Disease: What Will It Take To Improve Outcome?

Archie Bleyer, University of Texas M. D. Anderson Cancer Center, Houston, TX

The Survivor Transition Challenge

Kevin Charles Oeffinger, University of Texas Southwestern Medical School, Dallas, TX

Sponsored jointly by the American Society of Pediatric Hematology/Oncology and the Pediatric Academic Societies

9:15am – 12:15pm

3301 Pediatric Rare Tumors

PAS/ASPHO Mini Course

Chair: Alberto S. Pappo, The Hospital for Sick Children, Toronto, Canada

This session will describe the epidemiology, clinical features and current initiatives for the study and treatment of rare pediatric tumors.

Dr. Brad Pollock will discuss the epidemiology of rare tumors in pediatrics and will highlight the current COG initiative to improve reporting of these tumors through the COG Registry. Dr. Michael LaQuaglia will discuss the clinical and biological aspects of pediatric colorectal carcinoma. Dr. Carlos Rodriguez-Galindo will discuss the clinicopathological features and therapeutic strategies for pediatric adrenocortical carcinoma and pediatric nasopharyngeal carcinoma and Dr. Alberto Pappo will discuss the clinicopathological features and collaborative treatment initiatives for pediatric melanoma.

Pediatric Adrenocortical Carcinoma and Pediatric Nasopharyngeal Carcinoma

Carlos Rodriguez-Galindo, St Jude Children's Research Hospital, Memphis, TN

Epidemiology of Pediatric Rare Tumors

Brad H. Pollock, University of Texas Health Science Center, San Antonio, TX

Pediatric Melanoma

Alberto S. Pappo, The Hospital for Sick Children, Toronto, Canada

Pediatric Colorectal Carcinoma

Michael LaQuaglia, Memorial Sloan Kettering Cancer Center, New York, NY

Sponsored jointly with the American Society of Pediatric Hematology/Oncology and the Pediatric Academic Societies

12:00pm – 3:00pm

PAS Educational Workshops

See the PAS Program, beginning on page 32 for details.

1:00pm – 3:00pm

Hematology/Oncology Platform I

PAS/ASPHO Original Science Abstracts

3:15pm – 5:15pm

3751 New Genetics of Childhood Acute Leukemia

PAS/ASPHO Topic Symposium

Chair: Valerie Castle, University of Michigan, Ann Arbor, MI

Exciting new advances in gene expression analysis and animal models of childhood ALL and AML have opened the way for the emerging prospect of new forms of targeted therapy for childhood leukemia.

Genetic Models of AML and New Therapeutic Approaches

D. Gary Gilliland, Harvard Medical School, Boston, MA

Gene Expression Arrays in B-Lineage ALL and AML

James R. Downing, St. Jude Children's Research Hospital, Memphis, TN

New Genetics of T-Cell ALL: A Fish Tale

A. Thomas Look, Dana Farber Cancer Institute, Boston, MA

Sponsored jointly by the American Society of Pediatric Hematology/Oncology and the Pediatric Academic Societies

5:15pm – 7:15pm

Hematology/Oncology Posters I PAS Poster Session I, PAS Opening Reception & Exhibits

PAS/ASPHO Original Science Abstracts

Sunday, May 4, 2003

7:00am – 8:00am

Meet the Professor Breakfasts

TICKETED EVENTS

- Advance Sign Up Required.
- Attendance is limited to maintain the intimate interactive format and only 25 tickets will be assigned to each of these special sessions. These sessions will fill quickly.
- To register, use the registration form provided in the PAS or ASPHO brochures.

4051 Hematology/Oncology

Academic Careers in Pediatric Hematology/Oncology: The Next 20 Years

George J. Dover, Johns Hopkins Hospital, Baltimore, MD

Dr. Dover's background has been in hematology, genetics and clinical trials. He is now a Department Chair and will discuss the future of academic pediatrics in regard to subspecialists, especially those in hematology.

8:00am – 10:00am

Hematology/Oncology Platform II

PAS/ASPHO Original Science Abstracts

8:00am – 10:00am

PAS Educational Workshops

See the PAS Program, beginning on page 32 for details.

11:45am – 1:45pm

Hematology/Oncology Posters II PAS Poster Session II & Exhibits

PAS/ASPHO Original Science Abstracts

2:00pm–4:00pm

PAS Educational Workshops

See the PAS Program, beginning on page 32 for details.

2:30pm – 4:00pm

4732 Primary Immunodeficiency Diseases, a Hematologic and Molecular Approach

PAS/ASPHO State of the Art Plenary

Chair: Laurence A. Boxer, University of Michigan Medical Center, Ann Arbor, MI

The objective of this symposium is to better understand the molecular and genetic basis of three prototypes of Primary Immunodeficiency Disorders that are of interest to hematologists and the curious pediatrician. Exploring the function of the genes involved in these rare disorders not only contributes to the understanding of the clinical phenotypes but also may lead to improved treatment and ultimately will make gene therapy a reality.

Dr. Notarangelo will describe the different phenotypes of the known Hyper-IgM Syndromes and correlate the clinical findings with the molecular defects associated with these diseases. He will discuss in detail the consequences of mutations of CD40 ligand and its receptor, CD40, on activation of B and T cells and will dissect the molecular events resulting from mutations of activation induced cytidine deaminase (AID) and NEMO.

The clinical spectrum of symptoms associated with mutations of WASP, the gene responsible for the Wiskott Aldrich Syndrome (WAS) if mutated, will be presented in the second talk. An attempt will be made to correlate mutations of WASP with clinical phenotypes and ultimate outcome.

In the last talk, Dr. Puck will discuss the consequences of the immune dysregulation caused by defects in the cell death pathway and the genetic basis for Autoimmune Lymphoproliferative Syndrome (ALPS).

Of Genes and Phenotypes: The Clinical, Molecular and Immunological Spectrum of Immunodeficiency with Hyper-IgM

Luigi D. Notarangelo, University of Brescia, Brescia, Italy

The Wiskott-Aldrich Syndrome, a Challenge for the Hematologist

Hans D. Ochs, University of Washington School of Medicine, Seattle, WA

Autoimmune Lymphoproliferative Disease: When Lymphocytes Don't Die as They Should

Jennifer M. Puck, National Human Genome Research Institute/National Institutes of Health, Bethesda, MD

Sponsored jointly by the American Society of Pediatric Hematology/Oncology and the Pediatric Academic Societies

4:15pm – 6:15pm

4852 "Home from War" – Follow Up Post Hematopoietic Stem Cell Transplant

PAS/ASPHO Topic Symposium

Chair: Nancy Bunin, The Children's Hospital of Philadelphia, Philadelphia, PA

Children return to their referring hematologists/oncologists or pediatricians for follow up post hematopoietic stem cell transplant (HSCT). This session will discuss some of the issues, both immediate and long-term, that these children face. Many patients may require special care due to chronic graft vs. host disease, and the current treatment, challenges and particular infectious concerns of these patients will be discussed. Immune reconstitution post HSCT will be described, with presentation of newer therapies to accelerate reconstitution. Finally, survivors of HSCT are at risk for multiple endocrinologic abnormalities, including growth failure, hypogonadism and hypothyroidism. The endocrinologic follow-up of these patients and current intervention will be discussed.

Chronic GVHD and Associated Infections

Paul Carpenter, Fred Hutchinson Cancer Research Center, Seattle, WA

Enhancing Immune Reconstitution with IL7

Crystal L. Mackall, National Cancer Institute, Bethesda, MD

Growth and Endocrine Disturbances in Survivors of Hematopoietic Stem Cell Transplantation

Charles A. Sklar, Memorial Sloan-Kettering Cancer Center, New York, NY

Sponsored jointly by the American Society of Pediatric Hematology/Oncology and the Pediatric Academic Societies

ASPH/O

The American Society of
Pediatric Hematology/Oncology